Intervention not reported
Mortality within the longest · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
The intervention showed no clear difference in mortality within the longest (low certainty).
1 finding from 1 review
Intervention not reported
Mortality within the longest · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
It is very uncertain whether the intervention changes mortality within the longest (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality within 30 days of · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
1 finding from 1 review
Intervention not reported
Mortality within 30 days of · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
1 finding from 1 review
Intervention not reported
Surgical site infection within 30 days in trials with low risk of bias (14 days to 30 days) · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
The intervention showed no clear difference in surgical site infection within 30 days in trials with low risk of… (low certainty).
1 finding from 1 review
Intervention not reported
Surgical site infection within 30 days, irrespective of risk of bias (14 days to 30 days) · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
The intervention showed no clear difference in surgical site infection within 30 days, irrespective of risk of bias… (low certainty).
1 finding from 1 review
Intervention not reported
Respiratory insufficiency · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
The intervention showed no clear difference in respiratory insufficiency (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain (at study completion) WOMAC (VAS or NRS) from 0 to 20; lower scores mean reduced pain · People with hip or knee osteoarthritis
1 finding from 1 review
Intervention not reported
Physical function (at study completion) WOMAC (self administered health status measure) from 0 to 68; lower scores mean better function · People with hip or knee osteoarthritis
1 finding from 1 review
Intervention not reported
Adverse effects (related to the exercise programs) · People with hip or knee osteoarthritis
It is very uncertain whether the intervention changes adverse effects (related to the exercise programs) (very low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ duration exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Pain ‐ resistance exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ duration exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ resistance exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
SAEs · adults with asthma
ICS + LAMA add‐on showed no clear difference in SAEs (all cause) compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations leading to ED visits · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review